Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy -: A Swedisih multicenter study

被引:156
作者
Sjöblom, L
Hårdemark, HG [1 ]
Lindgren, A
Norrving, B
Fahlén, M
Samuelsson, M
Stigendal, L
Stockelberg, D
Taghavi, A
Wallrup, L
Wallvik, J
机构
[1] Univ Uppsala Hosp, Ctr Clin Neurosci, Dept Neurol, S-75185 Uppsala, Sweden
[2] Univ Uppsala Hosp, Dept Internal Med, S-75185 Uppsala, Sweden
[3] Univ Lund Hosp, Dept Neurol, S-22185 Lund, Sweden
[4] Orebro Univ Hosp, Orebro, Sweden
[5] Kungalv Hosp, Dept Internal Med, Kungalv, Sweden
[6] Sahlgrens Univ Hosp, Dept Internal Med, S-41345 Gothenburg, Sweden
[7] Cent Hosp Molndal, Dept Internal Med, Molndal, Sweden
[8] Falun Cent Hosp, Falu, Sweden
[9] Sundsvall Hosp, Sundsvall, Sweden
关键词
anticoagulants; cerebral hemorrhage; prognosis; tomography; x-ray computed;
D O I
10.1161/hs1101.098523
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Patients treated with oral anticoagulants (ACs) have an increased risk of intracerebral hemorrhage (ICH), which is more often fatal than spontaneous ICH. Options to reverse the AC effect include intravenous administration of vitamin K, plasma, and coagulation factor concentrate. However, the optimal management of AC-related ICH has not been determined in any randomized trial. In this study, the present management of AC-related ICH was surveyed, and determinants of survival were assessed. Methods-We retrospectively reviewed the medical records of all AC-related ICHs at 10 Swedish hospitals during a 4-year period, 1993 to 1996. Survival status after the ICH was determined from the Swedish National population register. Results-We identified 151 patients with AC-related ICH. Death rates were 53.6% at 30 days, 63.6% at 6 months, and 77.5% at follow-up (mean 3.5 years). The case fatality ratio at 30 days was 96% among patients unconscious on admission (n=27), 80% among patients who became unconscious before active treatment was started (n=15), 55% among patients in whom no special action was taken except withdrawal of AC treatment (n=42), and 28% among patients given active anti-coumarin treatment while they were still conscious (n=64). The case fatality, ratio at 30 days was 11% in the group treated with plasma (n = 18), 30% in the group treated with vitamin K (n = 23), and 39% in the group treated with coagulation factor concentrate (n=23). Within the first 24 to 48 hours after admission, 47% of the patients deteriorated. Choice of therapy to reverse the AC effect differed substantially between the hospitals (P <0.0001), as did the time interval from symptom onset to start of treatment. Multiple logistic regression analysis showed only 2 factors (intraventricular extension of bleeding and ICH volume) that were independently related to case fatality at both 30 days and 6 months. The results were similar when the analysis was restricted to patients who were conscious on admission. Conclusions-In AC-related ICH, a progressive, neurological deterioration during the first 24 to 48 hours after admission is frequent, and the mortality is high. Choice of therapy to reverse the AC effect differed considerably between the hospitals. There was no evidence that any treatment strategy was superior to the others. A randomized controlled trial is needed to determine the best choice of treatment.
引用
收藏
页码:2567 / 2574
页数:8
相关论文
共 42 条
  • [1] [Anonymous], STROKE PATHOPHYSIOLO
  • [2] Prediction of functional outcome and in-hospital mortality after admission with oral anticoagulant-related intracerebral hemorrhage
    Berwaerts, J
    Dijkhuizen, RS
    Robb, PJ
    Webster, J
    [J]. STROKE, 2000, 31 (11) : 2558 - 2562
  • [3] Use of factor IX complex in warfarin-related intracranial hemorrhage
    Boulis, NM
    Bobek, MP
    Schmaier, A
    Hoff, JT
    [J]. NEUROSURGERY, 1999, 45 (05) : 1113 - 1118
  • [4] Guidelines for the management of spontaneous intracerebral hemorrhage - A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association
    Broderick, JP
    Adams, HP
    Barsan, W
    Feinberg, W
    Feldmann, E
    Grotta, J
    Kase, C
    Krieger, D
    Mayberg, M
    Tilley, B
    Zabramski, JM
    Zuccarello, M
    [J]. STROKE, 1999, 30 (04) : 905 - 915
  • [5] Early hemorrhage growth in patients with intracerebral hemorrhage
    Brott, T
    Broderick, J
    Kothari, R
    Barsan, W
    Tomsick, T
    Sauerbeck, L
    Spilker, J
    Duldner, J
    Khoury, J
    [J]. STROKE, 1997, 28 (01) : 1 - 5
  • [6] Management of oral anticoagulant-induced intracranial haemorrhage
    Butler, AC
    Tait, RC
    [J]. BLOOD REVIEWS, 1998, 12 (01) : 35 - 44
  • [7] PROGRESSION OF HYPERTENSIVE INTRACEREBRAL HEMORRHAGE
    CHEN, ST
    CHEN, SD
    HSU, CY
    HOGAN, EL
    [J]. NEUROLOGY, 1989, 39 (11) : 1509 - 1514
  • [8] Egberg N, 1999, Lakartidningen, V96, P2489
  • [9] FELDMAN E, 1994, INTRACEREBRAL HEMORR
  • [10] Predicting deterioration in patients with lobar haemorrhages
    Flemming, KD
    Wijdicks, EFM
    St Louis, EK
    Li, HZ
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 66 (05) : 600 - 605